Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.32%168.130.7%$1126.81m
PFEPfizer Inc. 0.20%49.370.9%$915.46m
LLYEli Lilly & Co. 0.02%316.921.1%$811.12m
MRKMerck & Co., Inc. 0.65%91.600.7%$792.68m
ABBVAbbVie, Inc. -0.11%141.301.9%$791.44m
BMYBristol-Myers Squibb Co. 0.13%74.651.0%$639.37m
SIGASIGA Technologies, Inc. -1.18%24.480.0%$461.45m
AZNAstraZeneca Plc 0.53%66.771.0%$365.98m
GBTGlobal Blood Therapeutics, Inc. 0.03%67.025.6%$344.90m
GSKGSK Plc -0.40%34.540.3%$290.85m
ALNYAlnylam Pharmaceuticals, Inc. 1.29%226.008.2%$273.52m
VERUVeru, Inc. -2.82%23.110.0%$237.11m
HZNPHorizon Therapeutics Plc 1.15%62.445.4%$224.64m
CCXIChemoCentryx, Inc. 0.14%50.852.9%$208.67m
KRTXKaruna Therapeutics, Inc. 0.76%263.210.0%$205.79m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.